Compass Pathways (NASDAQ: CMPS) surged to a two-year valuation high in mid-May 2026 following major financial and clinical milestones. This aggressive market activity reflects a…
Beyond its anti-inflammatory and analgesic properties, previous preclinical studies have unveiled broader potential for Mira-55 in neurological and neuropsychiatric domains. Research has shown that Mira-55…